ALFA Finder| Management target | Revenue FY27 |
|---|
| Revenue growth | 8.6% YoY in FY26; 64% HoH growth in H2FY26. |
|---|---|
| Margins | EBITDA margin at 16.39%; PAT margin at 9.86%. |
| Demand visibility | Strong recovery in H2FY26; demand fully restored with 6300+ practitioners. |
| Management confidence | High; management highlights 'delivered as promised' after H1FY26 turnaround. |
Growth
FY26 Revenue reached INR 67 Cr with EBITDA margin improving 42 bps to 16.39%. H2FY26 saw significant 64% HoH sales recovery.
Outlook
Targeting expansion from 18 to 75 clinics by FY27 and 300 clinics long-term. Focusing on high-margin owned brands.
Risks
Historically impacted by demonetization, IL&FS default, COVID-19, and Ukraine war; currently tightening credit terms to manage receivables.
Earnings Call filed with NSE, NSE: AAKAAR. Summary written with AI assistance from the document.
Aakaar Medical Technologies Ltd: key numbers
- Share price
- ₹72.00
- Market cap
- ₹102.0 Cr
- Revenue (annual)
- ₹66.96 Cr
- Net profit (annual)
- ₹6.64 Cr
- P/E (TTM)
- 15.4×Sector 54.5×
- Promoter holding
- 67.05%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Aakaar Medical Technologies Ltd
All →Aakaar Medical Technologies Annual General Meeting
Aakaar Medical Technologies issued a Postal Ballot Notice seeking approval to appoint Mr. Abhash Meswani as Whole-Time Director with ₹50 lakh annual remuneration for five years.
Aakaar Medical Technologies Earnings Call Transcript: Key Takeaways
H1 FY27 revenue of ₹43.72 Cr (+72.64% YoY) and PAT of ₹3.54 Cr versus a prior loss. Margins were deliberately sacrificed for marketing and the distributor transition. Debtor days (219) and cash (₹1.05 Cr) are the key weak spots.
- Call
- Guides 36% growth
Aakaar Medical Technologies H1 FY27 Results: Turns Profitable, Net Profit ₹3.5 Cr
Aakaar Medical Technologies Ltd reported revenue from operations of ₹43.7 Cr (+72.7% YoY) and net profit of ₹3.5 Cr for H1 FY27.
- Key figure
- Net profit ₹3.5 Cr
Aakaar Medical Technologies Investor Presentation: Key Takeaways
H1 FY27 revenue ₹43.72 Cr (+72.6% YoY), EBITDA ₹5.43 Cr (12.42%), PAT ₹3.54 Cr vs prior loss ₹0.78 Cr. Strategy: doctor-led B2B2C distribution, Xelix clinic network, debtor-days reduction.
Aakaar Medical Technologies Board Meeting Date
Aakaar Medical Technologies Limited will hold a board meeting on 30-Oct-2026 to consider unaudited half-yearly financial results and ESOP matters.
Aakaar Medical Technologies Other Announcement
Aakaar Medical Technologies Limited submitted its Reconciliation of Share Capital Audit Report for the quarter ended September 30, 2026. The report confirms total issued capital remains at 1,41,72,816 equity shares.